Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report

doi:10.5306/wjco.v12.i4.272

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4459)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series.

Item

Count

PDF

376

WORD

156

HTML

2514

Figures (1-6)

296

Sum=3342

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

481

Download

636

Sum=1117

Apr 24, 2021 (publication date) through Jul 30, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Apr 24, 2021; 12(4): 272-281
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.272

Full Size Figure Download Figure

Figure 4 Positron emission tomography/computed tomography scan shows pulmonary metastases progression one year after treatment with sorafenib. PET: Positron emission tomography.

Citation: Butt MI, Khalid Bakhsh AM, Nadri QJ. Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report. World J Clin Oncol 2021; 12(4): 272-281
URL: https://www.wjgnet.com/2218-4333/full/v12/i4/272.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i4.272